Back to Browse Journals » International Journal of Nanomedicine » Volume 6

Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: target formulation development and in vitro anticancer activity

Authors Ding B, Wu X, Fan W, Wu Z, Gao J, Zhang W, Ma L, Xiang W, Zhu Q, Liu J, Ding X, Gao S

Published 15 September 2011 Volume 2011:6 Pages 1991—2005

DOI https://dx.doi.org/10.2147/IJN.S24094

Review by Single-blind

Peer reviewer comments 3

Baoyue Ding1,2, Xin Wu1, Wei Fan1,3, Zhaoyong Wu4, Jing Gao5, Wei Zhang1, Lulu Ma5, Wang Xiang1, Quangang Zhu1, Jiyong Liu1, Xueying Ding5, Shen Gao1
1Department of Pharmaceutics, Changhai Hospital, Second Military Medical University, Shanghai, 2Department of Pharmaceutics, Medical College of Jiaxing University, Jiaxing, 3The 425th Hospital of PLA, Department of Pharmacy, Sanya, 4Department of Pharmaceutics, Jiaxing Maternal and Childcare Hospital, Jiaxing, 5Department of Pharmaceutics, School of Pharmacy, Second Military Medical University, Shanghai, People's Republic of China
The first three authors contributed equally to this work.

Background: The increased incidence of malignant melanoma in recent decades, along with its high mortality rate and pronounced resistance to therapy pose an enormous challenge. Novel therapeutic strategies, such as immunotherapy and targeted therapy, are urgently needed for melanoma. In this study, a new active targeting drug delivery system was constructed to combine chemotherapy and active specifc immunotherapy.
Methods: The chemotherapeutic drug, dacarbazine (DTIC), that induces apoptosis through the intrinsic pathway which typically responds to severe DNA damage, was used as a model drug to prepare DTIC-loaded polylactic acid (PLA) nanoparticles (DTIC-NPs), which were covalently conjugated to a highly specific targeting functional TRAIL-receptor 2 (DR5) monoclonal antibody (mAb) that can contribute directly to cancer cell apoptosis or growth inhibition through the extrinsic pathway.
Results: Our in vitro experiments demonstrated that DTIC-PLA-DR5 mAb nanoparticles (DTIC-NPs-DR5 mAb) are an active targeting drug delivery system which can specifcally target DR5-overexpressing malignant melanoma cells and become efficiently internalized. Most strikingly, compared with conventional DTIC-NPs, DTIC-NPs-DR5 mAb showed significantly enhanced cytotoxicity and increased cell apoptosis in DR5-positive malignant melanoma cells.
Conclusion: The DTIC-NPs-DR5 mAb described in this paper might be a potential formulation for targeting chemotherapy and immunotherapy to DR5-overexpressing metastatic melanoma.

Keywords:
malignant melanoma, DR5 monoclonal antibodies, dacarbazine, apoptosis, chemoimmunotherapy, active targeting nanoparticles

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Reduction-responsive cross-linked stearyl peptide for effective delivery of plasmid DNA

Yao C, Tai Z, Wang X, Liu J, Zhu Q, Wu X, Zhang L, Zhang W, Tian J, Gao Y, Gao S

International Journal of Nanomedicine 2015, 10:3403-3416

Published Date: 8 May 2015

Study on the prostate cancer-targeting mechanism of aptamer-modified nanoparticles and their potential anticancer effect in vivo

Wu X, Tai Z, Zhu Q, Fan W, Ding B, Zhang W, Zhang L, Yao C, Wang X, Ding X, Li Q, Li X, Liu G, Liu J, Gao S

International Journal of Nanomedicine 2014, 9:5431-5440

Published Date: 21 November 2014

Degradable gene delivery systems based on Pluronics-modified low-molecular-weight polyethylenimine: preparation, characterization, intracellular trafficking, and cellular distribution

Fan W, Wu X, Ding B, Gao J, Cai Z, Zhang W, Yin D, Wang X, Zhu Q, Liu J, Ding X, Gao S

International Journal of Nanomedicine 2012, 7:1127-1138

Published Date: 24 February 2012

Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy

Wu X, Ding B, Gao J, Wang H, Fan W, Wang X, Zhang W, Wang X, Ye L, Zhang M, Ding X, Liu J, Zhu Q, Gao S

International Journal of Nanomedicine 2011, 6:1747-1756

Published Date: 19 August 2011

Readers of this article also read:

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Particle size reduction to the nanometer range: a promising approach to improve buccal absorption of poorly water-soluble drugs

Rao S, Song Y, Peddie F, Evans AM

International Journal of Nanomedicine 2011, 6:1245-1251

Published Date: 20 June 2011

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010